0.37  -0.047 (-11.27%)		05-01 16:00
Open: 0.4101 High: 0.4101 Volume: 395,868		Pre. Close: 0.417 Low: 0.3622 Market Cap: 10(M)

Short term
Mid term
Targets	6-month :	0.55	1-year :	0.64
Resists	First :	0.47	Second :	0.55
Pivot price	0.44
Supports	First :	0.36	Second :	0.29
MAs	MA(5) :	0.41	MA(20) :	0.44
	MA(100) :	0.39	MA(250) :	0
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	6.4	D(3) :	10.1
RSI	RSI(14): 34.9
52-week	High :	9.18	Low :	0.26

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CURX ] has closed below the lower bollinger band by 16.0%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 14.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.41 - 0.41	0.41 - 0.41
Low:	0.35 - 0.36	0.36 - 0.36
Close:	0.37 - 0.37	0.37 - 0.37

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. The company was founded in 1996 and is headquartered in Jericho, New York.

Fri, 27 Mar 2026
CURX Price Today: Curanex Pharmaceuticals Inc. Stock Price, Quote & Chart - MEXC

Thu, 06 Nov 2025
Curanex Pharmaceuticals receives Nasdaq notice on minimum bid price requirement - Investing.com

Fri, 12 Sep 2025
Curanex Pharmaceuticals Inc. Completes Successful IPO with Full Exercise of Over-Allotment Option, Raising Additional $2.25 Million | CURX Stock News - Quiver Quantitative

Wed, 27 Aug 2025
Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering - Yahoo Finance

Tue, 26 Aug 2025
CURX Stock Price, News & Analysis - Stock Titan

Sun, 03 May 2026

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	28 (M)
Shares Float	9 (M)
Held by Insiders	67.8 (%)
Held by Institutions	0 (%)
Shares Short	137 (K)
Shares Short P.Month	115 (K)

EPS	-0.02
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-30.1 %
Return on Equity (ttm)	-85.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-1 (M)
Levered Free Cash Flow	-1 (M)

PE Ratio	-18.5
PEG Ratio	0
Price to Book value	37
Price to Sales	0
Price to Cash Flow	-15.76

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.